529 research outputs found

    286. Leczenie raka sutka inhibitorami aromatazy II generacji w materiale WCO

    Get PDF
    Cel pracyInhibitory aromatazy II generacji (Letrozol, Anastrozol) s膮 stosowane w leczeniu zaawansowanego raka sutka, po niepowodzeniu leczenia tamoksifenem oraz coraz cz臋艣ciej jako leczenie pierwszego rzutu w leczeniu uzupe艂niaj膮cym. W pracy przedstawiono wst臋pne obserwacje i wyniki leczenia inhibitorami aromatazy chorych z nawrotem raka sutka oraz po niepowodzeniu leczenia tamoksifenem.Materia艂 i metody31 chorych na nowotw贸r sutka leczonych by艂o inhibitorami aromatazy II generacji w okresie od 01.01.1995 do 31.12.2000 roku w Wielkopolskim Centrum Onkologii. Wiek chorych si臋ga艂 od 43 do 85 lat (艣rednio 61.7 lat). Leczenie inhibitorami rozpocz臋to u 23 chorych z nawrotem raka sutka po niepowodzeniu leczenia tamoksifenem oraz u 8 chorych jako leczenie pierwszego rzutu. Wskazania do leczenia inhibitorami by艂y nast臋puj膮ce: rozsiew uog贸lniony (n=7 chorych), przerzuty do ko艣ci (n=7), wznowa miejscowa w bli藕nie (n=5), rak sutka zaawansowany, nieoperacyjny (n=3), przerzuty do w膮troby (n=3), do w臋z艂贸w ch艂onnych okolicy nadobojczykowej (n=2) oraz ze wzgl臋du na objawy uboczne tamoksifenu (n=4).Wyniki艢redni okres leczenia inhibitorami wynosi艂 13 miesi臋cy. W 7 przypadkach (22,6%) odst膮piono od dalszego leczenia z powodu: dalszej progresji w ko艣ciach (n=4), progresji guza w sutku (n=1), rozsiewu do OUN (n=1) i krwawienia z dr贸g rodnych (n=1). 艢redni czas do progresji od momentu rozpocz臋cia leczenia wynosi艂 9 miesi臋cy (w granicach od 1 do 24 miesi臋cy).WniosekInhibitory aromatazy II generacji wp艂ywaj膮 na zahamowanie rozwoju nawrotowego oraz zaawansowanego raka sutka u cz臋艣ci chorych. Tolerancja leczenia jest dobra

    Hair transplantation for the treatment of post-irradiation alopecia

    Get PDF

    338. Brachyterapia paliatywna PDR i HDR w leczeniu nawrot贸w miejscowych nowotwor贸w g艂owy i szyi

    Get PDF
    Cel pracyW pracy przedstawiono wst臋pne wyniki paliatywnej brachyterapii HDR i PDR wzn贸w nowotwor贸w g艂owy i szyi.Materia艂 i metody47 chorych ze wznow膮 miejscow膮 nowotworu g艂owy i szyi leczonych by艂o metod膮 brachyterapii HDR i PDR w okresie od 05.06.2001 do 31.12.2002 w Wielkopolskim Centrum Onkologii. Wszyscy chorzy zdyskwalifikowani zostali od leczenia chirurgicznego i radioterapii wi膮zkami zewn臋trznymi ze wzgl臋du na zaawansowanie choroby oraz przebyte leczenie. Wiek chorych si臋ga艂 od 38 do 75 (艣rednio 51.2 lat), w grupie by艂o 10 kobiet i 37 m臋偶czyzn. Umiejscowienie wznowy nowotworu: dno jamy ustnej i j臋zyk 鈥 20 chorych, gard艂o 艣rodkowe 鈥 12 chorych, w臋z艂y ch艂onne szyi 鈥 5 chorych, krta艅 鈥 3 chorych, nosogard艂o 鈥 3 chorych, 艣linianki 鈥 2 chorych, szcz臋ka g贸rna 鈥 2 chorych. 艢redni okres pomi臋dzy rozpoznaniem guza pierwotnego oraz wznowy wynosi艂 9.7 miesi臋cy. 34 chorych leczonych by艂o metod膮 brachyterapii HDR dawk膮 frakcyjn膮 od 4 do 6 Gy, w 5 do 10 frakcjach, 13 chorych leczonych by艂o metod膮 brachyterapii PDR dawka 艂膮czn膮 2000 cGy, w jednej (n=4) lub dw贸ch fazach leczenia (n=9). Ocenie poddano stopie艅 remisji po 1, 3 i 6-iu miesi膮cach od zako艅czenia leczenia oraz powik艂ania wczesne.WynikiPo 4-ech tygodniach od zako艅czenia leczenia ca艂kowit膮 remisj臋 (CR) stwierdzono u 15% chorych, cz臋艣ciow膮 remisj臋 (PR) u 65.1% chorych, brak remisji (NR) u 10.9% chorych i progresj臋 (Progr) u 9% chorych. Odpowiednie odsetki odpowiedzi wynosi艂y: po 3 i 6 miesi膮cach CR 鈥 10.3 i 5.6%, PR 鈥 54% i 36.3%), NR i Progr 鈥 35.7% i 58.1%. W 74.6% przypadkach wyst膮pi艂a powierzchowna martwica w okresie 6 miesi臋cy obserwacji. Inne najcz臋stsze powik艂ania to nasilenie b贸lu (25%), infekcja miejscowa (44.3%), przetoka (6%). Obie metody brachyterapii by艂y w r贸wnym stopniu dobrze tolerowane.Wnioski1. Brachyterapia HDR lub PDR mo偶e by膰 efektywnym paliatywnym leczeniem wznowy nowotworu g艂owy i szyi. 2. Powik艂ania wczesne zwi膮zane z wysok膮 dawk膮 sumaryczn膮 napromieniania s膮 cz臋ste i wymagaj膮 intensywnego leczenia farmakologicznego

    A homology model of restriction endonuclease SfiI in complex with DNA

    Get PDF
    BACKGROUND: Restriction enzymes (REases) are commercial reagents commonly used in recombinant DNA technologies. They are attractive models for studying protein-DNA interactions and valuable targets for protein engineering. They are, however, extremely divergent: the amino acid sequence of a typical REase usually shows no detectable similarities to any other proteins, with rare exceptions of other REases that recognize identical or very similar sequences. From structural analyses and bioinformatics studies it has been learned that some REases belong to at least four unrelated and structurally distinct superfamilies of nucleases, PD-DxK, PLD, HNH, and GIY-YIG. Hence, they are extremely hard targets for structure prediction and homology-based inference of sequence-function relationships and the great majority of REases remain structurally and evolutionarily unclassified. RESULTS: SfiI is a REase which recognizes the interrupted palindromic sequence 5'GGCCNNNN^NGGCC3' and generates 3 nt long 3' overhangs upon cleavage. SfiI is an archetypal Type IIF enzyme, which functions as a tetramer and cleaves two copies of the recognition site in a concerted manner. Its sequence shows no similarity to other proteins and nothing is known about the localization of its active site or residues important for oligomerization. Using the threading approach for protein fold-recognition, we identified a remote relationship between SfiI and BglI, a dimeric Type IIP restriction enzyme from the PD-DxK superfamily of nucleases, which recognizes the 5'GCCNNNN^NGGC3' sequence and whose structure in complex with the substrate DNA is available. We constructed a homology model of SfiI in complex with its target sequence and used it to predict residues important for dimerization, tetramerization, DNA binding and catalysis. CONCLUSIONS: The bioinformatics analysis suggest that SfiI, a Type IIF enzyme, is more closely related to BglI, an "orthodox" Type IIP restriction enzyme, than to any other REase, including other Type IIF REases with known structures, such as NgoMIV. NgoMIV and BglI belong to two different, very remotely related branches of the PD-DxK superfamily: the 伪-class (EcoRI-like), and the 尾-class (EcoRV-like), respectively. Thus, our analysis provides evidence that the ability to tetramerize and cut the two DNA sequences in a concerted manner was developed independently at least two times in the evolution of the PD-DxK superfamily of REases. The model of SfiI will also serve as a convenient platform for further experimental analyses

    Crystal structure and mechanism of action of the N6-methyladenine-dependent type IIM restriction endonuclease R.DpnI.

    Get PDF
    DNA methylation-dependent restriction enzymes have many applications in genetic engineering and in the analysis of the epigenetic state of eukaryotic genomes. Nevertheless, high-resolution structures have not yet been reported, and therefore mechanisms of DNA methylation-dependent cleavage are not understood. Here, we present a biochemical analysis and high-resolution DNA co-crystal structure of the N(6)-methyladenine (m6A)-dependent restriction enzyme R.DpnI. Our data show that R.DpnI consists of an N-terminal catalytic PD-(D/E)XK domain and a C-terminal winged helix (wH) domain. Surprisingly, both domains bind DNA in a sequence- and methylation-sensitive manner. The crystal contains R.DpnI with fully methylated target DNA bound to the wH domain, but distant from the catalytic domain. Independent readout of DNA sequence and methylation by the two domains might contribute to R.DpnI specificity or could help the monomeric enzyme to cut the second strand after introducing a nick

    Positive maps, positive polynomials and entanglement witnesses

    Full text link
    We link the study of positive quantum maps, block positive operators, and entanglement witnesses with problems related to multivariate polynomials. For instance, we show how indecomposable block positive operators relate to biquadratic forms that are not sums of squares. Although the general problem of describing the set of positive maps remains open, in some particular cases we solve the corresponding polynomial inequalities and obtain explicit conditions for positivity.Comment: 17 pages, 1 figur

    Optimal entanglement witnesses from generalized reduction and Robertson maps

    Get PDF
    We provide a generalization of the reduction and Robertson positive maps in matrix algebras. They give rise to a new class of optimal entanglement witnesses. Their structural physical approximation is analyzed. As a byproduct we provide a new examples of PPT (Positive Partial Transpose) entangled states.Comment: 14 page

    DNA Barcoding Identifies Unknown Females and Larvae of Fannia R.-D. (Diptera: Fanniidae) from Carrion Succession Experiment and Case Report.

    Full text link
    Application of available keys to European Fanniidae did not facilitate unequivocal species identification for third instar larvae and females of Fannia Robineau-Desvoidy, 1830 collected during a study of arthropod succession on pig carrion. To link these samples to known species, we took the advantage of molecular identification methods and compared newly obtained cytochrome oxidase subunit I (COI) barcode sequences against sequences deposited in reference databases. As an outcome of the results obtained, we describe for the first time a third instar larva of Fannia nigra Malloch, 1910 and Fannia pallitibia (Rondani, 1866) and a female of Fannia collini d'Assis-Fonseca, 1966. We provide combinations of characters allowing for discrimination of described insects from other Fanniidae. We provide an update for the key by Rozko拧n媒 et al. 1997, which allows differentiation between females of F. collini and other species of Fanniidae. Additionally, we provide a case of a human cadaver discovered in Southern Poland and insect fauna associated with it as the first report of F. nigra larvae developing on a human body
    corecore